Singapore-based biomedical company Cuprina Holdings announced on May 22 that it will implement a 1-for-8 reverse stock split for its Class A and Class B ordinary shares. The action is expected to take effect on or around May 27. The primary purpose of this move is to bring the company's share price back into compliance with Nasdaq's minimum $1.00 bid price requirement, thereby preserving its listing status.

The company's Chief Executive Officer, David Quek, stated that this is a crucial step to maintain the Nasdaq listing and enhance long-term financial flexibility. Under the consolidation plan, every eight shares of ordinary stock with a par value of $0.001 will be combined into one share with a par value of $0.008. No fractional shares will be issued in connection with the reverse split; any fractional shares resulting from the consolidation will be rounded up to the next whole share. The company's Class A shares will continue trading on Nasdaq under the ticker symbol "CUPR," but will be assigned a new CUSIP number.

The company received a notification from Nasdaq in November 2025, granting a 180-day compliance period, which expires on May 26, 2026, to address the issue of its share price remaining below the $1.00 minimum requirement. This reverse stock split represents the company's final attempt to regain compliance. According to public data, the stock has declined approximately 94% over the past year. Its current price is around $0.25, a significant drop from its 52-week high of $9.50.

While the reverse stock split will not alter any shareholder's proportional ownership in the company, its fundamental challenges remain significant. Financial reports show revenue for the first half of 2025 was only $18,000, a 40% year-over-year decline, with the net loss widening to approximately $1.53 million. The company's full-year revenue guidance is only between $1.0 million and $1.5 million. Furthermore, its market capitalization has fallen to approximately $6 million.